Avadel (AVDL)

Company Description

Avadel (AVDL – Flamel Technologies) is a specialty pharmaceutical company that combines unique proprietary drug delivery platforms and niche specialty pharmaceutical products with the goal of delivering safer, more efficacious formulations to address unmet medical needs. AVDL is currently headquartered in Lyon, France, but is expected to complete a transition to an Irish domicile near term, as AVDL divested itself of its French manufacturing facility in December 2014. AVDL also has operations in St. Louis, Missouri. AVDL has several drug delivery platforms under patent that include Medusa and Micropump, with derivatives LiquiTime and Trigger Lock. Medusa consists of an injectable, self-assembled poly-amino-acid nanogel that allows for multi-day extendedrelease dosing. The  Micropump system consists of enclosing the active ingredients in a microparticle that can then be put in a capsule or in a suspension or syrup. The Micropump technology is utilized in both LiquiTime and Trigger Lock. LiquiTime takes the coated microparticle and puts it in solution, allowing for an accurate release profile for up to 24 hours. This is designed for children or elderly patients who might have difficulties swallowing pills. Trigger Lock is a nanoparticle technology that may prevent drug abusers from misusing opioids by preventing tablet crushing and other common methods of abuse.

Published Reports

AVDL restructuring rev
AVDL 3Q18 rev
AVDL-2Q18-rev.pdf
Nocdurna avdl rev
AVDL-1Q18-rev.pdf
AVDL 4Q17 rev
AVDL FY18 guidance rev
AVDL 3Q17 rev
AVDL 2Q17 rev2
AVDL 4Q16 rev
AVDL 2017 guidance 1 5 17 rev_JFM
FLML ndr 12 7 16 rev
flml-3q16-rev2
flml-rd-day-9-26-16-rev
FLML 2Q16 rev
FLML.management notes.5.19.16 rev
FLML 1Q16 rev
FLML 4Q15 3.10.16 rev
FLML model update 1 21 16 rev
FLML 3Q15 rev
FLML.2Q15.7.31.15 rev
FLML Management day 6 29 15edit_JFM edits rev
FLML initiation of coverage 5 26 15-final rev